Concord Drugs Unveils ₹188.7 Mn Capital Infusion Plan via Warrants & Equity Issue

Concord Drugs Ltd has announced a dual capital-raising initiative totaling ₹188.7 million, aimed at strengthening its balance sheet and funding future growth. The board has approved the issuance of 2 million convertible warrants and 3.2 million equity shares, both priced at ₹36.30 per unit.

 

The warrants, aggregating ₹73.5 million, will be allotted on a preferential basis and are convertible into equity shares within a stipulated period. Simultaneously, the equity share issuance, worth ₹115.2 million, will be offered to select investors, likely including promoters and strategic partners.

 

This move is expected to enhance liquidity, support working capital needs, and potentially fund expansion in the company’s formulation and contract manufacturing verticals. The pricing reflects a moderate premium over recent trading levels, signaling investor confidence in Concord’s long-term prospects.

 

The capital raise aligns with Concord’s broader strategy to scale operations, improve R&D capabilities, and deepen its footprint in regulated markets.

 

Key Highlights:

Source: Capital Market – Concord Drugs Bonus & Equity Issue Update